Table 1.
Sample characteristicsa
| JIA group | |
| Sample size, no. | 74 |
| Total MRIs | 114 |
| Total joints | 211 |
| Age at JIA diagnosis, mean ± SD years | 7.24 ± 4.24 |
| Age at MRI, mean ± SD years | 13.19 ± 3.78 |
| Female | 61 (82) |
| Family autoimmune disease history | 48 (65) |
| JIA subtype | |
| Psoriatic | 27 (36) |
| Oligoarticular | 22 (30) |
| Polyarticular | 19 (26) |
| Systemic | 6 (8) |
| Medication exposure | |
| Methotrexate | 25 (34) |
| Nonsteroidal antiinflammatory drugs | 14 (19) |
| Adalimumab | 10 (14) |
| Leflunomide | 7 (9) |
| Etanercept | 7 (9) |
| Sulfasalazine | 5 (7) |
| Infliximab | 4 (5) |
| Prednisone | 2 (3) |
| Control group | |
| Sample size, no. | 71 |
| Total MRIs | 71 |
| Total joints | 142 |
| Age at MRI, mean ± SD years | 11.4 ± 3.5 |
| Female | 38 (54) |
| MRI type | |
| Temporal bone | 60 (85) |
| Optic nerve | 11 (15) |
| Indication for MRI | |
| Sensorineural hearing loss | 27 (38) |
| Cholesteatoma | 13 (18) |
| Facial nerve palsy | 11 (16) |
| Otalgia | 9 (13) |
| Optic neuropathy | 8 (11) |
| Papilledema | 3 (4) |
a
Values are the no. (%) unless otherwise indicated. JIA = juvenile idiopathic arthritis; MRI = magnetic resonance imaging.